Format

Send to

Choose Destination
Leukemia. 2017 Mar;31(3):565-572. doi: 10.1038/leu.2016.267. Epub 2016 Oct 3.

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis.

Author information

1
Department of Haematology, University Hospital of Toulouse, University of Toulouse, Centre of Research on Cancer of Toulouse (CRCT), Toulouse, France.
2
Groupe Francophone de Cytogénétique Hématologique (GFCH), Paris, France.
3
Department of Pediatric Oncology, University Hospital of Toulouse, Toulouse, France.
4
Department of Haematology, University Hospital of Saint-Louis, Paris, France.
5
Department of Haematology, Hospices Civils de Lyon, Lyon, France.
6
Department of Haematology, University Hospital of Haut-Leveque, Bordeaux, France.
7
Department of Haematology, University Hospital of Hautepierre, Strasbourg, France.
8
Department of Medical Genetic, University Hospital of La Timone, Marseille, France.
9
Department of Medical Genetic, University Hospital Jeanne de Flandre, University of Lille 2, Lille, France.
10
Department of Genetic, University Hospital Bretonneau, Tours, France.
11
Department of Oncology Genetic, Cancer Institute Henri Becquerel, Rouen, France.
12
Department of Haematology, University Hospital of Saint-Étienne, Saint-Etienne, France.
13
Department of Genetic, University Hospital Necker, Paris, France.
14
Department of Genetic, University Hospital Saint-Jacques, Besancon, France.
15
Department of Haematology, University Hospital Robert Debré, Reims, France.
16
Department of Cytogenetic, University Hospital of Dijon, Dijon, France.
17
Department of Haematology, Oncology and Immunology, University Hospital of Grenoble, Grenoble, France.
18
Department of Pediatric Oncology, University Hospital of Trousseau, Paris, France.

Abstract

Pediatric acute myeloid leukemia (AML) is a rare disease whose prognosis is highly variable according to factors such as chromosomal abnormalities. Recurrent genomic rearrangements are detected in half of pediatric AML by karyotype. NUcleoPorin 98 (NUP98) gene is rearranged with 31 different fusion partner genes. These rearrangements are frequently undetected by conventional cytogenetics, as the NUP98 gene is located at the end of the chromosome 11 short arm (11p15). By screening a series of 574 pediatric AML, we detected a NUP98 rearrangement in 22 cases (3.8%), a frequency similar to CBFB-MYH11 fusion gene (4.0%). The most frequent NUP98 fusion gene partner is NSD1. These cases are homogeneous regarding their biological and clinical characteristics, and associated with bad prognosis only improved by bone marrow transplantation. We detailed the biological characteristics of these AML by exome sequencing which demonstrated few recurrent mutations (FLT3 ITD, WT1, CEBPA, NBPF14, BCR and ODF1). The analysis of the clonal structure in these cases suggests that the mutation order in the NUP98-rearranged pediatric AML begins with the NUP98 rearrangement leading to epigenetic dysregulations then followed by mutations of critical hematopoietic transcription factors and finally, activation of the FLT3 signaling pathway.

PMID:
27694926
DOI:
10.1038/leu.2016.267
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center